Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.294,94 +742,78 (+1,98%) EUR/USD
1,0711 +0,0007 (+0,06%) Bitcoin EUR
62.315,25 -168,34 (-0,27%) CMC Crypto 200
1.430,86 +16,10 (+1,14%)
CorMedix Inc. (CRMD)
Dopo ore:
| Chiusura precedente | 5,28 |
| Aperto | 5,29 |
| Denaro | 5,40 x 400 |
| Lettera | 5,46 x 900 |
| Min-Max giorno | 5,26 - 5,58 |
| Intervallo di 52 settimane | 2,57 - 7,00 |
| Volume | |
| Media Volume | 596.730 |
| Capitalizzazione | 299,647M |
| Beta (5 anni mensile) | 1,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,91 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,00 |
GlobeNewswireCorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15. The abstract being presented highlights data regarding in vitro activity of taurolidine agains
- GlobeNewswire
CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023. Cantor Fitzgerald Global Healthcare Conference Date:Thursday,
- GlobeNewswire
CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology, or CJASN. The study compared the efficacy and safety of DefenCath®, a catheter lock solution that combines
